Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature

European Journal of Pediatrics

Volumn 175, Issue 1, 2016, Pages 9-18

  Bonnot, O ^a   Cohen, D ^b   Thuilleaux, D ^b   Consoli, A ^b   Cabal, S ^c   Tauber, M ^c  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Antidepressor; Antipsychotic; Methylphenidate; Prader Willi syndrome; Risperidone; Topiramate

Indexed keywords

ACETYLCYSTEINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; MAZINDOL; NALTREXONE; PLACEBO; PSYCHOTROPIC AGENT; RIMONABANT; RISPERIDONE; TOPIRAMATE; CYSTINE; FRUCTOSE; N-MONOACETYLCYSTINE;

AGGRESSION; AUTOMUTILATION; BEHAVIOR DISORDER; CHECKLIST; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; MEDICAL LITERATURE; MEDLINE; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; PUBLICATION; REVIEW; SYSTEMATIC REVIEW; UNIPARENTAL DISOMY; YALE BROWN OBSESSIVE COMPULSIVE SCALE; ADOLESCENT; ANALOGS AND DERIVATIVES; PRADER-WILLI SYNDROME; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYSTINE; FRUCTOSE; HUMANS; PRADER-WILLI SYNDROME; PSYCHOTROPIC DRUGS; RISPERIDONE;

EID: 84954395404     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-015-2670-x     Document Type: Review

References (60)

1. Adams S, Penton-Voak IS, Harmer CJ, Holmes EA, Munafo MR (2013) Effects of emotion recognition training on mood among individuals with high levels of depressive symptoms: study protocol for a randomised controlled trial. Trials 14:161. doi:10.1186/1745-6215-14-161
2. Amrouche-Mekkioui I, Djerdjouri B (2012) N-acetylcysteine improves redox status, mitochondrial dysfunction, mucin-depleted crypts and epithelial hyperplasia in dextran sulfate sodium-induced oxidative colitis in mice. Eur J Pharmacol 691:209–217. doi:10.1016/j.ejphar.2012.06.014
3. Araki S, Ohji T, Shiota N, Dobashi K, Shimono M, Shirahata A (2010) Successful risperidone treatment for behavioral disturbances in Prader-Willi syndrome. Pediatrics international: official journal of the Japan Pediatric Society 52:e1–e3. doi:10.1111/j.1442-200X.2009.02996.x
4. Arbaizar B, Gomez-Acebo I, Llorca J (2008) Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen Hosp Psychiatry 30:471–475
5. Banga A, Connor DF (2012) Effectiveness of naltrexone for treating pathologic skin picking behavior in an adolescent with Prader-Willi syndrome. J Child Adolesc Psychopharmacol 22:396–398. doi:10.1089/cap.2012.0028
6. Beardsmore A, Dorman T, Cooper SA, Webb T (1998) Affective psychosis and Prader-Willi syndrome. J Intellect Disabil Res 42(Pt 6):463–471
7. Benarroch F, Hirsch HJ, Genstil L, Landau YE, Gross-Tsur V (2007) Prader-Willi syndrome: medical prevention and behavioral challenges. Child Adolesc Psychiatr Clin N Am 16:695–708. doi:10.1016/j.chc.2007.03.007
8. Benjamin E, Buot-Smith T (1993) Naltrexone and fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 32:870–873. doi:10.1097/00004583-199307000-00025
9. Bertella L, Girelli L, Grugni G, Marchi S, Molinari E, Semenza C (2005) Mathematical skills in Prader-Willi Syndrome. J Intellect Disabil Res 49:159–169
10. Biederman J, Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366:237–248. doi:10.1016/S0140-6736(05)66915-2
11. Boer H, Holland A, Whittington J, Butler J, Webb T, Clarke D (2002) Psychotic illness in people with Prader Willi syndrome due to chromosome 15 maternal uniparental disomy. Lancet 359:135–136
12. Buiting K (2010) Prader-Willi syndrome and Angelman syndrome. Am J Med Genet C: Semin Med Genet 154C:365–376. doi:10.1002/ajmg.c.30273
13. Butler MG, Smith BK, Lee J, Gibson C, Schmoll C, Moore WV, Donnelly JE (2013) Effects of growth hormone treatment in adults with Prader-Willi syndrome. Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society 23:81–87. doi:10.1016/j.ghir.2013.01.001
14. Clarke D (1998) Prader-Willi syndrome and psychotic symptoms: 2. A preliminary study of prevalence using the Psychopathology Assessment Schedule for Adults with Developmental Disability checklist. J Intellect Disabil Res 42(Pt 6):451–454
15. Deb S, Unwin G, Deb T (2014) Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. J Intellect Disabil Res. doi:10.1111/jir.12119
16. Dech B, Budow L (1991) The use of fluoxetine in an adolescent with Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 30:298–302. doi:10.1097/00004583-199103000-00020
17. Dolengevich Segal H, Rodriguez Salgado B, Conejo Garcia A, San Sebastian Cabases J (2006) Efficacy of topiramate in children and adolescent with problems in impulse control: preliminary results. Actas Esp Psiquiatr 34:280–282
18. Duggan L, Brylewski J (1999) Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review. J Intellect Disabil Res 43(Pt 2):94–104
19. Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J (2000) Risperidone in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 39:545–546. doi:10.1097/00004583-200005000-00004
20. Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J (2000) Risperidone in treating behavioural disturbances of Prader-Willi syndrome. Acta Psychiatr Scand 102:461–465
21. Dykens EM, Roof E (2008) Behavior in Prader-Willi syndrome: relationship to genetic subtypes and age. J Child Psychol Psychiatry 49:1001–1008
22. Fieldstone A, Zipf WB, Sarter MF, Berntson GG (1998) Food intake in Prader-Willi syndrome and controls with obesity after administration of a benzodiazepine receptor agonist. Obes Res 6:29–33
23. Francey SM, Nelson B, Thompson A, Parker AG, Kerr M, Macneil C, Fraser R, Hughes F, Crisp K, Harrigan S, Wood SJ, Berk M, McGorry PD (2010) Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophr Res 119:1–10
24. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M, speakers contributors at the Second Expert Meeting of the Comprehensive Care of Patients with PWS (2008) Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 93:4183–4197. doi:10.1210/jc.2008-0649
25. Hassler F, Reis O (2010) Pharmacotherapy of disruptive behavior in mentally retarded subjects: a review of the current literature. Dev Disabil Res Rev 16:265–272. doi:10.1002/ddrr.119
26. Herguner S, Mukaddes NM (2007) Psychosis associated with fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 46:944–945. doi:10.1097/chi.0b013e318068fbed
27. Itoh M, Koeda T, Ohno K, Takeshita K (1995) Effects of mazindol in two patients with Prader-Willi syndrome. Pediatr Neurol 13:349–351
28. Jauregi J, Arias C, Vegas O, Alen F, Martinez S, Copet P, Thuilleaux D (2007) A neuropsychological assessment of frontal cognitive functions in Prader-Willi syndrome. J Intellect Disabil Res 51:350–365
29. Kennedy GM, Lhatoo SD (2008) CNS adverse events associated with antiepileptic drugs. CNS Drugs 22:739–760
30. Khan A, Faught E, Gilliam F, Kuzniecky R (1999) Acute psychotic symptoms induced by topiramate. Seizure 8:235–237
31. Kohn Y, Weizman A, Apter A (2001) Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine. Int J Eat Disord 30:113–117
32. Kyriakides M, Silverstone T, Jeffcoate W, Laurance B (1980) Effect of naloxone on hyperphagia in Prader-Willi syndrome. Lancet 1:876–877
33. Lee YJ, Marcu S, Berall G, Shapiro CM (2011) Tryptophan for the treatment of excessive daytime sleepiness in Prader-Willi syndrome. Indian Pediatr 48:319–321
34. Lin G, Lawrence R (2006) Pediatric case report of topiramate toxicity. Clin Toxicol (Phila) 44:67–69
35. Matthews SC, Miller BP (2001) Auditory hallucinations associated with topiramate. J Clin Psychiatry 62:653
36. Miller JL, Angulo M (2014) An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome. Am J Med Genet A 164:421–424. doi:10.1002/ajmg.a.36306
37. Morgan JR, Storch EA, Woods DW, Bodzin D, Lewin AB, Murphy TK (2010) A preliminary analysis of the phenomenology of skin-picking in Prader-Willi syndrome. Child Psychiatry Hum Dev 41:448–463. doi:10.1007/s10578-010-0180-7
38. Motaghedi R, Lipman EG, Hogg JE, Christos PJ, Vogiatzi MG, Angulo MA (2011) Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome. Eur J Med Genet 54:14–18. doi:10.1016/j.ejmg.2010.09.015
39. Mula M, Trimble MR, Lhatoo SD, Sander JW (2003) Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 44:659–663
40. Orphanet (2013) Prevalence of rare diseases. http://www.orpha.net/orphacom/cahiers/docs/FR/Prevalence_des_maladies_rares_par_prevalence_decroissante_ou_cas.pdf. Accessed January 2014
41. Rana F, Gormez A, Varghese S (2013) Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities. The Cochrane database of systematic reviews 4:CD009084. doi:10.1002/14651858.CD009084.pub2
42. Reas DL, Grilo CM (2008) Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring) 16:2024–2038
43. Reis AD, Castro LA, Faria R, Laranjeira R (2008) Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 30:132–135
44. Schepis C, Failla P, Siragusa M, Palazzo R, Romano C (1998) Failure of fluoxetine to modify the skin-picking behaviour of Prader-Willi syndrome. Australas J Dermatol 39:57–58
45. Selikowitz M, Sunman J, Pendergast A, Wright S (1990) Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial. Arch Dis Child 65:112–114
46. Semenza C, Pignatti R, Bertella L, Ceriani F, Mori I, Molinari E, Giardino D, Malvestiti F, Grugni G (2008) Genetics and mathematics: evidence from Prader-Willi syndrome. Neuropsychologia 46:206–212
47. Shapira NA, Lessig MC, Lewis MH, Goodman WK, Driscoll DJ (2004) Effects of topiramate in adults with Prader-Willi syndrome. American journal of mental retardation: AJMR 109:301–309. doi:10.1352/0895-8017(2004)109<301:EOTIAW>2.0.CO;2
48. Shapira NA, Lessig MC, Murphy TK, Driscoll DJ, Goodman WK (2002) Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 5:141–145. doi:10.1017/S1461145702002833
49. Sinnema M, Boer H, Collin P, Maaskant MA, van Roozendaal KE, Schrander-Stumpel CT, Curfs LM (2011) Psychiatric illness in a cohort of adults with Prader-Willi syndrome. Res Dev Disabil 32:1729–1735. doi:10.1016/j.ridd.2011.02.027
50. Skokauskas N, Sweeny E, Meehan J, Gallagher L (2012) Mental health problems in children with prader-willi syndrome. Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l’Academie canadienne de psychiatrie de l’enfant et de l’adolescent 21:194–203
51. Smathers SA, Wilson JG, Nigro MA (2003) Topiramate effectiveness in Prader-Willi syndrome. Pediatr Neurol 28:130–133
52. Soni S, Whittington J, Holland AJ, Webb T, Maina E, Boer H, Clarke D (2007) The course and outcome of psychiatric illness in people with Prader-Willi syndrome: implications for management and treatment. J Intellect Disabil Res 51:32–42. doi:10.1111/j.1365-2788.2006.00895.x
53. Soni S, Whittington J, Holland AJ, Webb T, Maina EN, Boer H, Clarke D (2008) The phenomenology and diagnosis of psychiatric illness in people with Prader-Willi syndrome. Psychol Med 38:1505–1514
54. Stella F, Caetano D, Cendes F, Guerreiro CA (2002) Acute psychotic disorders induced by topiramate: report of two cases. Arq Neuropsiquiatr 60:285–287
55. Unwin GL, Deb S (2011) Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: a systematic review. Res Dev Disabil 32:2121–2133. doi:10.1016/j.ridd.2011.07.031
56. Van Borsel J, Defloor T, Curfs LM (2007) Expressive language in persons with Prader-Willi syndrome. Genet Couns 18:17–28
57. Vogels A, Matthijs G, Legius E, Devriendt K, Fryns JP (2003) Chromosome 15 maternal uniparental disomy and psychosis in Prader-Willi syndrome. J Med Genet 40:72–73
58. Whitman BY, Accardo P (1987) Emotional symptoms in Prader-Willi syndrome adolescents. Am J Med Genet 28:897–905
59. Whittington J, Holland A, Webb T, Butler J, Clarke D, Boer H (2004) Academic underachievement by people with Prader-Willi syndrome. J Intellect Disabil Res 48:188–200
60. Wu K, Hanna GL, Easter P, Kennedy JL, Rosenberg DR, Arnold PD (2013) Glutamate system genes and brain volume alterations in pediatric obsessive-compulsive disorder: a preliminary study. Psychiatry Res 211:214–220. doi:10.1016/j.pscychresns.2012.07.003